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Abstract
Background: Acute kidney injury (AKI) is a multifactorial syndrome, but knowledge about its pathophysiology and
possible genetic background is limited. Recently the first hypothesis-free genetic association studies have been
published to explore individual susceptibility to AKI. We aimed to replicate the previously identified associations between
five candidate single nucleotide polymorphisms (SNP) in apoptosis-related genes BCL2, SERPINA4, SERPINA5, and SIK3 and
the development of AKI, using a prospective cohort of critically ill patients with sepsis/septic shock, in Finland.
Methods: This is a prospective, observational multicenter study. Of 2567 patients without chronic kidney disease and
with genetic samples included in the Finnish Acute Kidney Injury (FINNAKI) study, 837 patients had sepsis and 627
patients had septic shock. AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria,
considering stages 2 and 3 affected (severe AKI), stage 0 unaffected, and stage 1 indecisive. Genotyping was done using
iPLEXTM Assay (Agena Bioscience). The genotyped SNPs were rs8094315 and rs12457893 in the intron of the BCL2 gene,
rs2093266 in the SERPINA4 gene, rs1955656 in the SERPINA5 gene and rs625145 in the SIK3 gene. Association analyses
were performed using logistic regression with PLINK software.
Results: We found no significant associations between the SNPs and severe AKI in patients with sepsis/septic shock,
even after adjustment for confounders. Among patients with septic shock (252 with severe AKI and 226 without AKI
(149 with KDIGO stage 1 excluded)), the SNPs rs2093266 and rs1955656 were significantly (odds ratio 0.63, p = 0.04276)
associated with stage 2–3 AKI after adjusting for clinical and demographic variables.
Conclusions: The SNPs rs2093266 in the SERPINA4 and rs1955656 in the SERPINA5 were associated with the development
of severe AKI (KDIGO stage 2–3) in critically ill patients with septic shock. For the other SNPs, we did not confirm the
previously reported associations.
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Background
In critically ill patients, the incidence of acute kidney injury
(AKI) is high - 39% in the recent prospective, observa-
tional, multicenter study, the Finnish Acute Kidney Injury
(FINNAKI) study, which was conducted in Finnish inten-
sive care units (ICUs) [1]. In other prospective studies in
critically ill patients the incidence of AKI is reported as
24–66% [2, 3]. Although the pathophysiology of AKI has
been investigated, there is no single explanation for the
condition due to the multifactorial nature of the syndrome.
Sepsis is the most common factor predisposing to AKI in
the critically ill. In patients with sepsis the incidence of
AKI is 31–53% [4–6] and in patients with septic shock it is
even higher, at 47–61% [7, 8]. The previously identified risk
factors for septic AKI, such as age, sex, and baseline
comorbidities, have failed to reliably predict individual risk
of septic AKI [9]. Thus, it is plausible that genetic
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variability between individuals may explain a significant
part of the risk.
Genetic predisposition to AKI has been previously stu-
died in candidate genes, by testing associations between
single nucleotide polymorphisms (SNP) from candidate
genes and a phenotype. Our recent systematic review con-
firmed that despite some positive associations there are no
conclusive data [10]. A study by Frank et al. [11] provided
one of the very first hypothesis-free approaches to septic
AKI; it comprised 887 patients in septic shock defined ac-
cording to American College of Chest Physicians/Society
of Critical Care Medicine (ACCP/SCCM) criteria [12],
who were genotyped using a large-scale genotyping micro-
array. In this study, five SNPs were associated with AKI
after validating the results in an additional sample. Inter-
estingly, the associated SNPs are in the apoptosis pathway
genes. The SNP rs8094315 and SNP rs12457893 are
located in the intron of B-cell CLL/lymphoma 2 (BCL2) –
gene. The SNPs rs2093266 in the serpin peptidase inhibi-
tor, clade A (alpha-1 antiproteinase, antitrypsin), member
4 (SERPINA4) gene and SNP rs1955656 in the serpin pep-
tidase inhibitor, clade A (alpha-1 antiproteinase, antitryp-
sin), member 5 (SERPINA5) gene are in complete linkage
disequilibrium (LD). There was also association between
the SNP rs625145 in the salt-inducible kinase family 3
(SIK3) gene and AKI. In this study we aimed to replicate
the aforementioned findings [9] in a prospective cohort of
critically ill patients with sepsis.
Methods
Study population
This study is a predetermined genetic study of the
prospective, observational, multicenter FINNAKI study, in
which patients were recruited from 17 Finnish ICUs.
Details of the FINNAKI study have been published
elsewhere [1] and are presented in Additional file 1. The
Ethics Committee of the Department of Surgery in
Helsinki University Hospital approved the study. An in-
formed separate written consent for genetic samples was
obtained from the patient or next of kin at the initiation,
with the option of deferred consent. The main study
ended on 1 February 2012, and recruitment was extended
until 30 April 2012 to achieve an adequate number of pa-
tients with sepsis. The study was conducted according to
the Declaration of Helsinki.
Data collection
We collected the study-specific data items (approximately
80% of the data) on admission and daily until day 5 or
ICU discharge using an electronic case report form (CRF).
Data comprised previous and current health status, medi-
cation, risk factors for AKI, laboratory values and opera-
tions preceding ICU admission, sepsis and related organ
dysfunctions, and focus of infection. Presence of AKI and/
or sepsis was screened until ICU discharge or day 5 at the
latest if the patient was still in the ICU. Routine data were
collected with the help of the Finnish Intensive Care
Consortium, which consists of 25 ICUs nationwide.
Definitions
For staging of AKI, plasma creatinine was measured
daily and urine output hourly. We defined and staged
AKI according to the new Kidney Disease: Improving
Global Outcomes (KDIGO) AKI criteria [13]. We sought
to compare patients with a severe phenotype of AKI
(KDIGO stage 2–3) to patients with no AKI. Thus, we
excluded patients with KDIGO stage-1 AKI from the
current analysis because their phenotype may be seen as
indecisive. We defined sepsis and septic shock according
to the ACCP/SCCM definitions [12], a definition also
used in the previous report [11].
Blood sampling and DNA extraction
Whole blood was collected at enrollment and after
separation of plasma, stored at -80 °C for subsequent
DNA extraction. DNA was isolated on a Chemagic 360
instrument (Perkin Elmer, Baesweiler, Germany), based
on magnetic bead technology, using a Chemagic DNA
Blood10k Kit according to the manufacturer’s instruc-
tions. DNA concentrations were determined using UV
light and PicoGreen methods, and samples were diluted
into 10 ng/μl for genotyping.
Genotype analysis
Genotyping was performed at the Technology Centre of
the Institute for Molecular Medicine Finland (FIMM),
University of Helsinki. The genotyping was done using
Agena MassARRAY® system and the iPLEXTM Gold
Assay (Agena BioscienceTM, San Diego, CA, USA). This
method has excellent success (>95%) and accuracy
(100%) [14]. Genotyping reactions were performed on
20 ng of dried genomic DNA in 384-well plates accord-
ing to the manufacturer’s recommendations and using
their reagents [15]. Both polymerase chain reaction
(PCR) and extension primers were designed using Mas-
sARRAY Assay Design software (Agena BioscienceTM)
(Additional file 2). The data were collected using the
MassARRAY Compact System (Agena BioscienceTM)
and the genotypes were called using TyperAnalyzer
software (Agena BioscienceTM).
We examined genotyping quality by a detailed quality
control procedure consisting of success rate check, du-
plicated samples, water controls, and Hardy-Weinberg
equilibrium (HWE) testing. In addition, the genotype
calls were checked manually and corrected when neces-
sary. Genotyping personnel were blinded to the clinical
status of the patients.
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Statistical analysis
We compared the clinical and demographic variables
to test for significant differences between groups
using the Fisher exact test for categorical variables
and the Mann-Whitney U test for continuous vari-
ables. We present data as medians and interquartile
ranges, or absolute values and percentages. Statistical
analyses of the demographic and clinical variables
were performed using the SPSS Statistics version 22
(IBM Corp., Armonk, NY, USA).
Associations between AKI and SNP were adjusted for
clinical characteristics that differed significantly between
patients with and without AKI. In addition to the univari-
ate analysis we performed multivariate analysis using logis-
tic regression by entering variables, selecting characteristics
with a p value <0.2 in univariate analysis. The percentage
of missing data was 15.9%. The missing data were imputed
on the assumption of being unaffected for categorical
variables and on the median for continuous variables.
Genetic association tests were performed using logistic
regression and the PLINK software [16]. As in the previ-
ous study an additive genetic model was assumed. How-
ever, confirmatory tests were performed using recessive
and dominant genetic models. In the primary analysis
patients with sepsis and AKI (KDIGO stage 2–3) were
compared to patients with sepsis but no AKI. Secondary
analyses were performed including cases and controls
from the entire cohort, and was performed separately
only in those with septic shock. As this was a replication
study, we considered all p values <0.05 significant.
Power calculations
Power calculations were made using Genetic Power Cal-
culator [17], assuming allele frequencies and odds ratios
from the validation cohort from the study by Frank et al.
[11], and with the assumption of 299 patients and 354
controls, a prevalence of AKI of 39,% and a type I error
rate of 0.005. For detailed power calculations for each
SNP see Additional file 3.
Results
Patients
We prospectively enrolled 2968 ICU patients in the FIN-
NAKI genetic study, as presented in the study flowchart
(Fig. 1). After excluding ineligible patients, there were
2567 critically ill patients, of whom 837 (32.6%) had sep-
sis. Of these, 299 (35.7% of the 837) patients developed
KDIGO stage 2–3 AKI and 354 (42.3% of 837) patients
with no AKI served as controls (Fig. 1, orange dashed
line). Thus, the genetic associations were studied among
653 patients with sepsis, of whom 478 (73.2%) had septic
shock. Among patients with septic shock, 252 (40.2% of
627) had severe AKI and 226 (36.0% of 627) did not have
AKI (Fig. 1, red dashed line). In the entire genetic cohort,
there were 601 (23.4% of 2567) patients who developed
KDIGO stage 2–3 AKI and 1545 (60.2% of 2567) patients
who did not develop AKI (Fig. 1, blue dashed line).
The baseline characteristics of the patients with sepsis
who did and did not have AKI are presented in Table 1.
The baseline characteristics of the patients with septic
shock who did and did not have AKI are presented in
Table 2. The baseline characteristics of the entire cohort
are presented in Additional file 4.
Genetic associations
All of the polymorphisms tested were in HWE. None of
the five SNPs investigated, rs8094315 (odds ratio (OR)
1.10, p = 0.48), rs12457893 (OR 1.02, p = 0.87), rs2093266
Fig. 1 Study flowchart. AKI acute kidney injury, KDIGO Kidney Disease: Improving Global Outcomes, FINNAKI Finnish Acute Kidney Injury study
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Table 1 Demographic and baseline characteristics of the patients with sepsis according to the presence of acute kidney injury
Characteristics Patients with data
available, n
KDIGO 0
(n = 354)
KDIGO 2–3
(n = 299)
All patients
(n = 653)
P value
Age (years) 653 63 (52–73) 65 (54.5–75) 63 (53–74) 0.046
Gender (male) 653 234 (66.1%) 183 (61.2%) 417 (63.9%) 0.195
BMI (kg/m2) 651 26.0 (23.1–29.2) 27.3 (24.5–30.8) 26.5 (23.5–29.6) 0.001
Arterial hypertension 651 164 (46.6%) 159 (53.2%) 323 (49.6%) 0.099
Diabetes 653 68 (19.2%) 82 (27.4%) 150 (23.0%) 0.015
Arteriosclerosis 648 36 (10.3%) 42 (14.1%) 78 (12.0%) 0.147
COPD 649 45 (12.8%) 19 (6.4%) 64 (9.9%) 0.008
Chronic liver disease 647 17 (4.9%) 24 (8.1%) 41 (6.3%) 0.106
Systolic heart failure 649 39 (11.1%) 24 (8.1%) 63 (9.7%) 0.231
Thromboembolus 649 26 (7.4%) 17 (5.7%) 43 (6.6%) 0.432
Rheumatic disease 648 26 (7.4%) 18 (6.1%) 44 (6.8%) 0.534
Serum creatinine
Baseline (μmol/L) 653 80.3 (68.0–94.0) 77.0 (66.5–93.0) 79.0 (67.0–93.2) 0.318
Maximum (μmol/L) 604 72.0 (55.0–89.0) 227.0 (166.0–321.0) 106.5 (68.5–221.5) <0.001
Pre-ICU daily medication
ACE inhibitor or ARB 640 113 (32.6%) 115 (39.2%) 228 (35.6%) 0.082
NSAID 624 33 (9.7%) 42 (14.7%) 75 (12.0%) 0.064
Aspirin 645 81 (23.1%) 73 (24.7%) 154 (23.9%) 0.644
Diuretic 643 93 (26.8%) 88 (29.7%) 181 (28.1) 0.429
Metformin 647 48 (13.7%) 47 (15.8%) 95 (14.7%) 0.504
Statin 644 86 (24.6%) 79 (26.8%) 165 (25.6%) 0.587
Immunosuppressives 646 29 (8.3%) 28 (9.5%) 57 (8.8%) 0.581
Corticosteroids 649 41 (11.6%) 32 (10.8%) 73 (11.2%) 0.803
Warfarin 647 39 (11.1%) 41 (13.8%) 80 (12.4%) 0.338
Treatments administered 48 h
before admission
Contrast medium 652 83 (23.5%) 51 (17.1%) 134 (20.6%) 0.052
Aminoglycoside antibiotics 653 4 (1.1%) 5 (1.7%) 9 (1.4%) 0.739
Peptidoglycan antibiotics 653 17 (4.8%) 11 (3.7%) 28 (4.3%) 0.563
ACE inhibitor or ARB 641 77 (22.1%) 72 (24.7%) 149 (23.2%) 0.454
NSAID 615 52 (15.6%) 40 (14.2%) 92 (15.0%) 0.651
Amfoterisin B 653 1 (0.3%) 2 (0.7%) 3 (0.5%) 0.596
Diuretics 637 119 (34.6%) 117 (39.9%) 236 (37.0%) 0.188
Colloids (gelatin or starch) 620 102 (30.8%) 117 (40.5%) 219 (35.3%) 0.015
Albumin 647 4 (1.1%) 6 (2.0%) 10 (1.5%) 0.526
Emergency admission 648 343 (98.0%) 292 (98.0%) 635 (98.0%) 1.0
Operative admission 652 88 (24.9%) 66 (22.1%) 154 (23.6%) 0.459
SAPS II score 24 h without
renal and age components
649 24.0 (17.0–30.0) 26.0 (20.0–37.0) 25.0 (18.0–33.0) <0.001
Mechanical ventilation 653 234 (66.1%) 221 (73.9%) 455 (69.7%) 0.033
White blood cell count,
maximum (109/L)
583 11.8 (7.9–16.5) 12.2 (7.6–17.8) 11.9 (7.7–17.2) 0.469
Platelet count, minimum (109/L) 632 199.5 (141.0–271.0) 184.0 (112.0–259.0) 191.5 (128.5–265.0) 0.028
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(OR 0.77, p = 0.15), rs1955656 (OR 0.77, p = 0.15), and
rs625145 (OR 0.88, p = 0.38), was significantly associated
with AKI in our analysis in patients with sepsis in the
additive genetic model (Table 3). The SNPs rs2093266 and
rs1955656 are in complete linkage disequilibrium (LD)
and thus present identical results.
In logistic regression analysis in patients with sepsis,
higher body mass index (BMI), not having chronic ob-
structive pulmonary disease (COPD), use of non-steroidal
anti-inflammatory drugs (NSAID) as daily medication,
administration of contrast medium prior to ICU admis-
sion, simplified acute physiology score II (SAPS II)
without renal or age components, and source of infection
were significantly associated with KDIGO stage 2–3 AKI
(Additional file 5). Adjustment for these clinical and
demographic factors in the patients with sepsis did not
change the results for genetic association, which were not
statistically significant (Table 3).
In patients with septic shock, none of the investigated
SNPs was significantly associated with AKI in univariate
analysis (Table 4). After adjusting for clinical and demo-
graphic variables that remained significant in logistic re-
gression (BMI, use of NSAID as daily medication,
arteriosclerosis, COPD, administration of contrast
medium prior to ICU admission, administration of col-
loids prior to ICU admission, SAPS II without age or
renal components, operative admission, and source of
infection (Additional file 6)) SNPs rs2093266 and
rs1955656 were significantly associated with AKI (OR
0.63, 95% CI 0.40 to 0.98, p = 0.043, for each) (Table 4,
Fig. 2). The carriers of the minor alleles of these SNPs
(A and A, respectively) had a decreased risk of develop-
ing AKI. This association was in the same direction as in
the previous report. The minor allele frequencies of all
investigated SNPs in patients with septic shock are
presented in Fig. 2.
When the same analyses were performed in the entire
genetic cohort, there was no evidence of association
between any of the SNPs and AKI in univariate or multi-
variate models when adjusting for clinical and demo-
graphic variables that remained significant in logistic
regression (Additional files 7 and 8).
Using recessive and dominant genetic models did not
change the results: SNPs rs8094315, rs12457893 and
rs625145 were not associated with AKI in any of the sub-
groups studied. The protective association with SNPs
rs2093266 and rs1955656 prevailed in patients in septic
shock in the dominant adjusted model (OR 0.59, p = 0.034,
for each) (Additional file 9). The self-assessed quality score
of the study was 9/10 [18] (Additional file 10).
Discussion
In this study we confirmed the previously reported asso-
ciation between AKI and two polymorphisms, rs2093266
and rs1955656 in apoptosis-related genes SERPINA 4
and SERPINA5 in patients with septic shock. Both in
our study and in the original study the minor alleles of
these SNPs provided protection from AKI. The associ-
ation signal was seen in both additive and dominant
genetic models but not in the recessive model, sugges-
ting that merely one protective allele is sufficient.
Our study was based on a previous report suggesting
that polymorphisms within apoptosis-related genes may
be associated with the development of AKI. In this study
comprising 887 patients with septic shock, AKI was
associated with five SNPs [11]. To our knowledge this is
the first successful replication of two of these SNPs.
There was no evidence in our cohort of significant asso-
ciation between AKI and the other three polymorphisms
tested, rs8094315, rs12457893, and rs625145.
The SNP rs2093266 is located in an intronic region of
SERPINA4 gene encoding kallistatin, a serine proteinase
inhibitor that has multiple regulatory roles in biological
processes [19, 20]. In kallistatin there are two functional
domains, an active site and a heparin-binding site, through
which it regulates several signaling and biological
Table 1 Demographic and baseline characteristics of the patients with sepsis according to the presence of acute kidney injury
(Continued)
Source of infection 653 <0.001
Lung 181 (51.1%) 100 (33.4%) 281 (43.0%)
Abdomen 62 (17.5%) 78 (26.1%) 140 (21.4%)
Urinary tract 10 (2.8%) 26 (8.7%) 36 (5.5%)
Skin 25 (7.1%) 26 (8.7%) 51 (7.8%)
Others 19 (5.4%) 9 (3.0%) 28 (4.3%)
Multiple sources 21 (5.9%) 16 (5.4%) 37 (5.7%)
Unknown source of infection 36 (10.2%) 44 (14.7%) 80 (12.3%)
Results presented as median (interquartile range) for continuous variables and total number (percent of affected in a group) for categorical variables. Continuous
variables analyzed by the independent samples Mann-Whitney U test and categorical variables by Fisher’s exact test. KDIGO Kidney Disease: Improving Global
Outcomes, BMI body mass index, COPD chronic obstructive pulmonary disease, ARB angiotensin receptor blocker, NSAID non-steroidal anti-inflammatory drug, ACE
angiotensin-converting enzyme, SAPS simplified acute physiology score
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Table 2 Demographic and baseline characteristics of patients with septic shock according to the presence of acute kidney injury
Characteristics Patients with data
available, n
KDIGO 0
(n = 226)
KDIGO 2–3
(n = 252)
All patients
(n = 478)
P value
Age (years) 478 63.0 (52.0–73.0) 64.5 (54.0–75.0) 63.5 (53.0–74.0) 0.138
Gender (male) 478 155 (68.6%) 156 (61.9%) 311 (65.1%) 0.149
BMI (kg/m2) 476 26.0 (23.0–29.0) 27.3 (24.5–30.5) 26.5 (23.5–29.5) 0.001
Arterial hypertension 476 104 (46.4%) 137 (54.4%) 241 (50.6%) 0.098
Diabetes 478 42 (18.6%) 65 (25.8%) 107 (22.4%) 0.062
Arteriosclerosis 475 21 (9.4%) 36 (14.3%) 57 (12.0%) 0.120
COPD 474 28 (12.5%) 19 (7.6%) 47 (9.9%) 0.090
Chronic liver disease 473 10 (4.5%) 22 (8.8%) 32 (6.8%) 0.069
Systolic heart failure 475 22 (9.8%) 22 (8.8%) 44 (9.3%) 0.752
Thromboembolus 475 14 (6.2%) 14 (5.6%) 28 (5.9%) 0.846
Rheumatic diseases 475 19 (8.5%) 17 (6.8%) 36 (7.6%) 0.493
Serum creatinine
Baseline (μmol/L) 478 82.5 (69.0–93.4) 77.0 (67.0–93.0) 79.7 (67.0–93.0) 0.236
Maximum (μmol/L) 478 69.0 (50.0–89.0) 226.5 (166.0–323.0) 113.5 (67.0–230.0) <0.0001
Pre-ICU daily medication
ACE inhibitor or ARB 465 78 (35.6%) 96 (39.0%) 174 (37.4%) 0.502
NSAID 453 21 (9.8%) 35 (14.6%) 56 (12.4%) 0.152
Aspirin 471 52 (23.4%) 59 (23.7%) 111 (23.6%) 1.000
Diuretic 468 57 (26.0%) 76 (30.5%) 133 (28.4%) 0.305
Metformin 473 30 (13.5%) 38 (15.2%) 68 (14.4%) 0.602
Statin 469 55 (24.9%) 61 (24.6%) 116 (24.7%) 1.000
Immunosuppressives 471 19 (8.5%) 26 (10.5%) 45 (9.6%) 0.531
Corticosteroids 474 26 (11.6%) 29 (11.6% 55 (11.6%) 1.000
Warfarin 472 26 (11.7%) 34 (13.6%) 60 (12.7%) 0.581
Treatments administered 48 h
before admission
Contrast medium 477 58 (25.8%) 46 (18.3%) 104 (21.8%) 0.059
Aminoglycoside antibiotics 478 2 (0.9%) 5 (2.0% 7 (1.5%) 0.455
Peptidoglycan antibiotics 478 12 (5.3%) 10 (4.0%) 22 (4.6%) 0.519
ACE inhibitor or ARB 468 43 (19.3%) 62 (25.3%) 105 (22.4%) 0.122
NSAID 448 28 (13.4%) 36 (15.1%) 64 (14.3%) 0.685
Amfoterisin B 478 0 (0.0%) 2 (0.8%) 2 (0.4%) 0.500
Diuretics 464 70 (32.1%) 97 (39.4%) 167 (36.0%) 0.121
Colloids (gelatin or starch) 452 76 (36.4%) 105 (43.2%) 181 (40.0%) 0.149
Albumin 474 4 (1.8%) 6 (2.4%) 10 (2.1%) 0.756
Emergency admission 474 217 (97.3%) 245 (97.6%) 462 (97.5%) 1.000
Operative admission 477 69 (30.5%) 58 (23.1%) 127 (26.6%) 0.078
SAPS II score 24 h without
renal and age components
475 25.0 (19.0–33.0) 26.0 (21.0–37.0) 26.0 (20.0–35.0) 0.054
Mechanical ventilation 478 177 (78.3%) 197 (78.2%) 374 (78.2%) 1.000
White blood cell count, maximum (109/L) 428 12.1 (8.7–16.8) 12.8 (7.6–18.7) 12.3 (8.1–17.4) 0.794
Platelet count, minimum (109/L) 458 191.0 (140.0–260.0) 177.0 (108.5–259.0) 185.0 (121.0–259.0) 0.065
Source of infection 478 0.001
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pathways. Along with its functions in relation to apop-
tosis, it has anti-inflammatory, antioxidant, vasodilator
and angiogenesis inhibiting functions [21]. All these
mechanisms are relevant in septic AKI and could thus ex-
plain the better outcome.
In recent mouse model studies, Kallistatin has been as-
sociated with attenuated inflammation and organ injury
and decreased mortality in established sepsis [22], and
with improved survival in sepsis-related acute lung
injury [23]. Of note, it may also have a renoprotective
role against diabetic nephropathy [24]. rs1955656 in
SERPINA5 is strongly correlated with rs2093266 and as
suspected before, this association with AKI could be
driven by rs2093266. Notably, the product of SERPINA5
is known to inhibit activated protein C. This protein C
inhibitor (PCI) plays a role in tumor growth and metas-
tasis through its effect on blood coagulation, but it has
also been suggested to inhibit the anti-inflammatory ac-
tivity of activated protein C [25, 26]. This inflammatory
function could possibly explain the protection against
septic AKI.
Of the other three SNPs studied, two (rs8094315 and
rs12457893) are located in the introns of the apoptosis-
related gene BCL2 encoding an integral outer mitochondrial
membrane protein BCL2 that blocks the apoptotic death of
certain cells [27]. The SNP rs625145 is in SIK3, coding for a
member of the AMP-activated protein kinase family that
affects the regulation of several genes. This protein is found
to suppress inflammatory molecule gene expression in mac-
rophages stimulated with lipopolysaccharides (LPS) [28].
There is no definite consensus on the pathophysiology
of AKI, and until recently the most common approach
has been to test for association with known genetic vari-
ants. These variants have often come up in another
phenotype, commonly chronic kidney disease, and, thus,
may serve as poor markers of AKI [29, 30]. So far, the
most studied polymorphisms are within inflammatory
mediator genes [10].
Apoptosis-related genes are good candidates for AKI
because there is some evidence that apoptosis is an
important mechanism in septic AKI. In a murine model
of septic AKI the pathophysiology appears to differ from
that of ischemia-reperfusion insult, lacking signs of
tubular cell injury by necrosis but showing a substantial
number of tubular cells undergoing apoptosis [31].
Lerolle et al. found that in post-mortem kidney biopsies
Table 2 Demographic and baseline characteristics of patients with septic shock according to the presence of acute kidney injury
(Continued)
Lung 114 (50.4%) 83 (32.9%) 197 (41.2%)
Abdomen 46 (20.4%) 68 (27.0%) 114 (23.8%)
Urinary tract 7 (3.1%) 20 (7.9%) 27 (5.6%)
Skin 16 (7.1%) 22 (8.7%) 38 (7.9%)
Others 11 (4.9) 8 (3.2%) 19 (4.0%)
Multiple sources 13 (5.8%) 14 (5.6%) 27 (5.6%)
Unknown source of infection 19 (8.4%) 37 (14.7%) 56 (11.7%)
Results presented as median (interquartile range) for continuous variables and total number (percent of affected in a group) for categorical variables. Continuous
variables analyzed by the independent samples Mann-Whitney U test and categorical variables by Fisher’s exact test. KDIGO Kidney Disease: Improving Global
Outcomes, BMI body mass index, COPD chronic obstructive pulmonary disease, ARB angiotensin receptor blocker, NSAID non-steroidal anti-inflammatory drug, ACE
angiotensin-converting enzyme, SAPS simplified acute physiology score
Table 3 Association between acute kidney injury and the polymorphisms studied in 653 patients with sepsis (additive genetic
model)
Univariate Multivariate
SNP Chr Base-pair position Gene and alleles
(major/minor)
Minor allele
frequencya
Odds ratio
(95% CI)
P value Odds ratio
(95% CI)b
P value
rs625145 11 116857220 SIK3 A/T 0.20/0.21 0.88 (0.67–1.17) 0.38 0.93 (0.68–1.25) 0.62
rs1955656 14 94579038 SERPINA5 G/A 0.10/0.12 0.77 (0.53–1.10) 0.15 0.75 (0.51–1.10) 0.14
rs2093266 14 94566450 SERPINA4 G/A 0.10/0.12 0.77 (0.53–1.10) 0.15 0.75 (0.51–1.10) 0.14
rs8094315 18 63268814 BCL2 A/G 0.24/0.22 1.10 (0.85–1.43) 0.48 1.08 (0.81–1.43) 0.61
rs12457893 18 63258928 BCL2 A/C 0.37/0.37 1.02 (0.81–1.29) 0.87 1.06 (0.82–1.36) 0.67
aPatients/controls. bAdjusted for age, body mass index, diabetes mellitus, mechanical ventilation, minimum platelet count, use of non-steroidal anti-inflammatory
drugs as daily medication, chronic pulmonary obstructive disease, administration of contrast medium prior to ICU admission, administration of colloids prior to
ICU admission, simplified acute physiology score II without age or renal components, operative admission, and source of infection. SNP single nucleotide
polymorphism, Chr chromosome
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of patients who died of septic shock (n = 19) there was a
marked increase in apoptosis and capillary leukocytic
infiltration in comparison with patients with trauma and
ICU controls [32]. However, there were contradicting
results in a separate sample of post-mortem kidney biop-
sies in patients who died of sepsis [33]. The nature of
septic AKI alone appears to be diverse, with temporal
and individual variation, and the role of apoptosis is
inconclusive [34].
We also tested the association between the five
SNPs and development of AKI in all patients with
sepsis, but the results were negative. The phenotype
of septic shock differs from that of sepsis without
shock, reflecting a more severe form of illness and a
greater risk of death. Thus, we can speculate that the
associations between SNPs and AKI detected in these
patients, although not generalizable to the septic co-
hort, can predict better survival for the carriers of the
protective allele in terms of AKI.
The strength of our study is that it was a prospective,
relatively large, multicenter study comprising consecu-
tive patients. In addition we used the KDIGO criteria to
provide a robust phenotype of AKI and critically ill
patients without AKI as controls to increase the power
of our study.
There are some important limitations in our study.
First, 171 genetic samples (5.8%) could not be analyzed
due to failure in the DNA isolation phase or to rejection
of samples because of a low genotyping success rate.
Second, we did not collect data ont ethnicity. However,
99.9% of Finnish-speaking inhabitants are Caucasian.
Third, individual genetic susceptibility factors can be
expected to increase the AKI risk with values just ex-
ceeding an OR of 1 [35]. In our power calculations we
used the ORs reported in the original study, and, thus,
our study might have been underpowered to replicate
the results for BCL2 and SIK3. Fourth, we did not adjust
the p values for multiple testing, in this replication of
positive findings.
Finally, in contrast to the previous study [11] we
excluded patients with chronic kidney disease. Further-
more, we aimed to strengthen the phenotype by compar-
ing patients without AKI to patients with more severe
AKI (KDIGO stage 2–3), thus excluding those with
KDIGO stage 1. We reasoned that this group would in-
clude patients with only KDIGO stage-1 urine output
Table 4 Association between acute kidney injury and the polymorphisms studied in 478 patients in septic shock (additive genetic model)
Single nucleotide
polymorphism
Univariate odds ratio
(95% confidence interval)
Univariate
P value
Multivariate odds ratio
(95% confidence interval)a
Multivariate
P value
rs625145 0.81 (0.59–1.11) 0.19 0.80 (0.56–1.13) 0.20
rs1955656 0.71 (0.46–1.07) 0.10 0.63 (0.40–0.98) 0.043
rs2093266 0.71 (0.46–1.07) 0.10 0.63 (0.40–0.98) 0.043
rs8094315 1.19 (0.88–1.62) 0.27 1.13 (0.81–1.58) 0.48
rs12457893 1.24 (0.94–1.62) 0.13 1.22 (0.91–1.64) 0.19
aAdjusted for body mass index, use of non-steroidal anti-inflammatory drugs as daily medication, arteriosclerosis, chronic obstructive pulmonary disease,
administration of contrast medium prior to ICU admission, administration of colloids prior to ICU admission, simplified acute physiology score II without age or
renal components, operative admission, and source of infection
Fig. 2 Minor allele frequencies of all polymorphisms studied in patients with septic shock (n = 478). Patients (red) had severe acute kidney injury
(AKI) (Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 or 3 AKI, n = 252) and controls (blue) were ICU patients without AKI. The
p values shown above the bars are for the multivariate tests of association between the polymorphisms and AKI. *Significant p values
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(not included in [11]) criteria, whose phenotype clearly
differs from that of more severe acute kidney.
These findings provide some interesting questions for
future research. The functions of the SNPs rs2093266 in
the SERPINA4 and rs1955656 in the SERPINA5 for the
protein products are yet to be determined. If further
studies can provide independent evidence supporting
the role of these SNPs in AKI susceptibility, information
about the genotype of either of these SNPs may add to
the battery of risk-predicting tools. However, the effect
size of the SNPs is too small for the genotype informa-
tion to work as an independent biomarker in a clinical
setting.
Conclusions
In this study we aimed to replicate the previous findings
associating polymorphisms within apoptosis-related
genes to AKI. We found that SNPs rs2093266 in the
SERPINA4 and rs1955656 in the SERPINA5 were associ-
ated with KDIGO stage 2–3 AKI in critically ill patients
in septic shock.
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